Effective approaches to address the global cardiovascular disease burden
暂无分享,去创建一个
Salim Yusuf | S. Yusuf | J. Schwalm | P. Lamelas | Pablo M Lamelas | J D Schwalm | J. Schwalm | Jon-David Schwalm
[1] D. Prabhakaran,et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. , 2013, JAMA.
[2] T. Patel,et al. A Community-Based Participatory Diabetes Prevention and Management Intervention in Rural India Using Community Health Workers , 2012, The Diabetes educator.
[3] W. Elliott. Community-Based Interventions to Promote Blood Pressure Control in a Developing Country: A Cluster Randomized Trial , 2010 .
[4] T. Novotny,et al. UN resolution on the prevention and control of non-communicable diseases: An opportunity for global action , 2011, Global public health.
[5] S. Yusuf,et al. Resource Effective Strategies to Prevent and Treat Cardiovascular Disease. , 2016, Circulation.
[6] S. Leeder,et al. Coronary heart disease epidemics: not all the same , 2008, Heart.
[7] S. Flottorp,et al. Tailored interventions to overcome identified barriers to change: effects on professional practice and health care outcomes. , 2005, The Cochrane database of systematic reviews.
[8] F. Cappuccio,et al. A community programme to reduce salt intake and blood pressure in Ghana [ISRCTN88789643] , 2006, BMC public health.
[9] Lynn A Smaha,et al. The American Heart Association Get With The Guidelines program. , 2004, American heart journal.
[10] Joint Learning Initiative,et al. Human resources for health : overcoming the crisis , 2004 .
[11] P. Cosgrove,et al. Cost-Effectiveness of Community-Based Strategies for Blood Pressure Control in a Low-Income Developing Country: Findings From a Cluster-Randomized, Factorial-Controlled Trial , 2011, Circulation.
[12] Mark D. Huffman,et al. Reducing Premature Cardiovascular Morbidity and Mortality in People With Atherosclerotic Vascular Disease: The World Heart Federation Roadmap for Secondary Prevention of Cardiovascular Disease. , 2015, Global heart.
[13] S. Kane,et al. Which intervention design factors influence performance of community health workers in low- and middle-income countries? A systematic review , 2014, Health policy and planning.
[14] B. Popkin,et al. First-Year Evaluation of Mexico’s Tax on Nonessential Energy-Dense Foods: An Observational Study , 2016, PLoS medicine.
[15] K. Hassell,et al. Affordability of medicines and patients’ cost-reducing behaviour , 2005, Applied health economics and health policy.
[16] P. Volberding,et al. Antiretroviral therapy and management of HIV infection , 2010, The Lancet.
[17] J. Hayden,et al. Interventions to improve adherence to cardiovascular disease guidelines: a systematic review , 2015, BMC Family Practice.
[18] S. Yusuf,et al. Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data , 2016, The Lancet.
[19] S. Yusuf,et al. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. , 2001, Circulation.
[20] S. Fleming,et al. Self-Screening and Non-Physician Screening for Hypertension in Communities: A Systematic Review , 2015, American journal of hypertension.
[21] Mohammad R. Ostovaneh,et al. Polypill for the prevention of cardiovascular disease (PolyIran): study design and rationale for a pragmatic cluster randomized controlled trial , 2015, European journal of preventive cardiology.
[22] S. Yusuf,et al. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial , 2009, The Lancet.
[23] Julia A. Critchley,et al. Explaining the Decrease in U.S. Deaths from Coronary Disease, 1980–2000 , 2004 .
[24] D. Prabhakaran,et al. Reducing Cardiovascular Mortality Through Prevention and Management of Raised Blood Pressure: A World Heart Federation Roadmap. , 2015, Global heart.
[25] M. Arora,et al. Reducing Cardiovascular Mortality Through Tobacco Control: A World Heart Federation Roadmap. , 2015, Global heart.
[26] S. Yusuf,et al. Comparison of Risk Factor Reduction and Tolerability of a Full-Dose Polypill (With Potassium) Versus Low-Dose Polypill (Polycap) in Individuals at High Risk of Cardiovascular Diseases: The Second Indian Polycap Study (TIPS-2) Investigators , 2012, Circulation. Cardiovascular quality and outcomes.
[27] Tezeta F. Mitiku,et al. Trends in risk factors for cardiovascular disease in Canada: temporal, socio-demographic and geographic factors , 2009, Canadian Medical Association Journal.
[28] S. Nishtar,et al. Can non-physician health-care workers assess and manage cardiovascular risk in primary care? , 2007, Bulletin of the World Health Organization.
[29] William H Shrank,et al. Patients' perceptions of generic medications. , 2009, Health affairs.
[30] Lisa Rosenbaum. Beyond belief--how people feel about taking medications for heart disease. , 2015, The New England journal of medicine.
[31] T. Puoane,et al. An assessment of community health workers’ ability to screen for cardiovascular disease risk with a simple, non-invasive risk assessment instrument in Bangladesh, Guatemala, Mexico, and South Africa: an observational study , 2015, The Lancet. Global health.
[32] O. Ergene,et al. Impact of a mass media campaign to increase public awareness of hypertension. , 2011, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.
[33] S. Yusuf,et al. Patients’ Knowledge, Attitudes, Behaviour and Health Care Experiences on the Prevention, Detection, Management and Control of Hypertension in Colombia: A Qualitative Study , 2015, PloS one.
[34] B. J. Gersh. Explaining the Decrease in U.S. Deaths from Coronary Disease, 1980–2000 , 2008 .
[35] R. Dandona,et al. The Rural Andhra Pradesh Cardiovascular Prevention Study (RAPCAPS): a cluster randomized trial. , 2012, Journal of the American College of Cardiology.
[36] L. Schwamm,et al. Hospital performance recognition with the Get With The Guidelines Program and mortality for acute myocardial infarction and heart failure. , 2009, American heart journal.
[37] J. Newell,et al. Action to Stop Smoking in Suspected Tuberculosis (ASSIST) in Pakistan , 2013, Annals of Internal Medicine.
[38] S. Witter,et al. Costs and cost-effectiveness of community health workers: evidence from a literature review , 2015, Human Resources for Health.
[39] S. Yusuf,et al. Reducing Cardiovascular Disease Globally: The World Heart Federation's Roadmaps. , 2015, Global heart.
[40] E. Vermeire,et al. The concept and definition of therapeutic inertia in hypertension in primary care: a qualitative systematic review , 2014, BMC Family Practice.
[41] S. Yusuf,et al. Controversies in cardiovascular medicine Why are we failing to implement effective therapies in cardiovascular disease ? , 2013 .
[42] Martin McKee,et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. , 2013, JAMA.
[43] C. Mathers,et al. Chronic disease prevention: health effects and financial costs of strategies to reduce salt intake and control tobacco use , 2007, The Lancet.
[44] L. Chambers,et al. Improving cardiovascular health at population level: 39 community cluster randomised trial of Cardiovascular Health Awareness Program (CHAP) , 2011, BMJ : British Medical Journal.
[45] Martin McKee,et al. Cardiovascular risk and events in 17 low-, middle-, and high-income countries. , 2014, The New England journal of medicine.
[46] P. Perel,et al. The Road to 25×25: Update on WHF CVD Roadmaps. , 2017, Global heart.
[47] M Arantxa Colchero,et al. Beverage purchases from stores in Mexico under the excise tax on sugar sweetened beverages: observational study , 2016, British Medical Journal.
[48] M. Cabana,et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. , 1999, JAMA.
[49] S. Yusuf,et al. Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. , 2016, The New England journal of medicine.
[50] Ashutosh Kumar Singh,et al. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 , 2016, Lancet.
[51] S. Yusuf,et al. Patient and Healthcare Provider Barriers to Hypertension Awareness, Treatment and Follow Up: A Systematic Review and Meta-Analysis of Qualitative and Quantitative Studies , 2014, PloS one.
[52] S. Yusuf,et al. Understanding the modifiable health systems barriers to hypertension management in Malaysia: a multi-method health systems appraisal approach , 2015, BMC Health Services Research.
[53] Ashutosh Kumar Singh,et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015 , 2016, The Lancet.
[54] The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions. , 2010, Circulation.
[55] F. Chaloupka,et al. The Impact of Prices and Taxes on the Use of Tobacco Products in Latin America and the Caribbean , 2018, Revista panamericana de salud publica = Pan American journal of public health.